News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 2204S

2204S 2.5 mg

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Western blot analysis of extracts from NIH/3T3 cells, untreated (-) or treated (+) with Bortezomib (100 nM, 6 hr), using Ubiquitin Antibody #3933 (left), p53 (1C12) Mouse mAb #2524 (middle), and β-Actin (13E5) Rabbit mAb #4970 (right).

Learn more about how we get our images

Chemical structure of Bortezomib.

Learn more about how we get our images

Western blot analysis of L363 cells, untreated (-) or treated (+) with Bortezomib (24 hr) as indicated, using K48-linkage Specific Polyubiquitin Antibody #4289.

Learn more about how we get our images
Image

Product Usage Information

Bortezomib is supplied as a lyophilized powder. For a 1 mM stock, reconstitute the 2.5 mg in 6.51 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 1-1000 nM for 2-48 hours. Soluble in DMSO and ethanol at 200 mg/ml, very poorly soluble in plain water.


Storage: Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight:

384.24 g/mol


Purity:

99%


Molecular Formula:

C19H25BN4O4


Bortezomib (C19H25BN4O4), a boronic acid dipeptide, is a specific, potent, and reversable proteasome inhibitor that has also been shown to have a stabilizing effect on proteins that inhibit cell survival and cell cycle progression, such as p53 (1,2). Researchers have demostrated that bortezomib inhibits activation and nuclear translocation of NF-κB, subsequently decreasing early tumor survival (3). The increase in bortezomib-stablilized, misfolded, and ubiquitinated proteins that interfere with cell survival and other important pathways further support its anti-tumor effects (3).


1.  Williams, S.A. and McConkey, D.J. (2003) Cancer Res 63, 7338-44.

2.  Poulaki, V. et al. (2007) Invest Ophthalmol Vis Sci 48, 4706-19.

3.  Mimnaugh, E.G. et al. (2004) Mol Cancer Ther 3, 551-66.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.